Cite
252P Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?
MLA
Noto, C., et al. “252P Does the Introduction of CDK4/6 Inhibitors (CDKi) in First-Line Treatment of Metastatic Breast Cancer (MBC) Increase Medical Oncology Workload?” Annals of Oncology, vol. 32, Sept. 2021, p. S470. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.08.535.
APA
Noto, C., Dri, A., Pravisano, F., Residori, M., Bortot, L., Buriolla, S., Targato, G., Andreetta, C., Pascoletti, G., Poletto, E., Russo, S., Mansutti, M., Minisini, A. M. M., Puglisi, F., Fasola, G., & Bonotto, M. (2021). 252P Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload? Annals of Oncology, 32, S470. https://doi.org/10.1016/j.annonc.2021.08.535
Chicago
Noto, C., A. Dri, F. Pravisano, M. Residori, L. Bortot, S. Buriolla, G. Targato, et al. 2021. “252P Does the Introduction of CDK4/6 Inhibitors (CDKi) in First-Line Treatment of Metastatic Breast Cancer (MBC) Increase Medical Oncology Workload?” Annals of Oncology 32 (September): S470. doi:10.1016/j.annonc.2021.08.535.